ACPE UAN #: 0233-0000-18-004-H01-P
Release Date: April 23, 2018
Expiration Date: April 23, 2021
Activity Type: Knowledge-based
Contact Hours: 1
Activity Fee: Member: $15 Non-Member: $30
Target Audience: Pharmacists who practice in managed care settings.
Over the past few decades, the treatment of hemophilia has been transformed by the emergence of safer clotting factor replacement products, and the growing use of prophylactic therapy to prevent bleeding and joint destruction. But current therapy is not without its limitations. Patients face a demanding schedule of multiple weekly infusions. And if they develop inhibitors—antibodies directed against the infused clotting factors—disease management becomes considerably more challenging, and the associated costs can be staggering. Agents in the pipeline seek to overcome these limitations through extended half-lives and novel non-factor replacement strategies. This session will provide a refresher on the pathophysiology of hemophilia, review current standards of treatment, and preview the role of promising new therapeutic options.
At the completion of this activity, participants should be able to:
- Recall the pathophysiology and clinical manifestations of hemophilia.
- Review the role and optimal use of currently available treatments for hemophilia.
- Identify patient- and disease-specific considerations for the selection of treatment.
- Discuss the mechanism of action, indications, efficacy and safety of high-impact hemophilia pipeline drugs.
Schedule of Educational Activity:
This activity consists of an audio recording, pre-test assessment questions (not required to pass or continue), post-test questions (required to pass with a score of 70% or higher) and a specific activity evaluation.
The Academy of Managed Care Pharmacy (AMCP) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
As an accredited provider, AMCP strictly adheres to the ACPE Standards for Commercial Support and other relevant guidelines and standards to ensure the independence of continuing pharmacy education (CPE) activities. It is AMCP’s intent that all CPE activities be independent, objective, balanced, evidence-based and free of any commercial bias.
Participants should claim continuing pharmacy education (CPE) credit for this home study activity only if they have not claimed credit for the live activity presented at Specialty Connect 2018.
CPE credit will be processed through the AMCP Learn portal and reported directly to CPE Monitor. Please allow 72 hours for processing and posting in your NABP account.
To receive credit for an online activity you must:
- Review the full content of the activity.
- Successfully complete the post-test (required to pass with a score of 70% or higher, it may be taken a maximum of three times).
- Complete a specific activity evaluation.
Statement of Commercial Support
This educational activity is supported by unrestricted educational grants from CSL Behring LLC, Novo Nordisk Inc. and Shire.
Susan C. Winckler | RPh, Esq. | President, Leavitt Partners Consulting | Chief Risk Management Officer | Leavitt Partners.
System Technical Requirements/Viewing Requirements: System Requirements Courses and learning activities are delivered via your Web browser and Acrobat PDF. For all activities, you should have a basic comfort level using a computer and navigating websites. View the minimum technical and system requirements for continuing education online learning activities.
|Activity Number||Credit Amount||Accreditation Period|
|ACPE UAN #0233-0000-18-004-H01-P||1 Contact Hour||April 23, 2018 - April 23, 2021|